

# Hysorptase<sup>®</sup> rHuPH20 technology

## An efficient platform of subcutaneous drug delivery

Corporate Presentation  
October 2024


# Recombinant human hyaluronidase - Hysorptase<sup>®</sup>

An enzyme that degrades hyaluronan (HA) locally in subcutaneous space

Hyaluronic Acid (HA) is naturally present in the subcutaneous tissue, filling spaces within the collagen matrix and creating a physical barrier that limits the spread and absorption of injected drugs.

## Limitations of Traditional Subcutaneous Injection:

- Low absorption rate
- Small injection volume (typically up to 2 mL per injection site)



Recombinant human hyaluronidase (rHuPH20) breaks down this barrier by degrading HA, allowing for greater flexibility in drug formulation and administration.

## SC injection with rHuPH20

- High absorption rate
- High-volume SC
- IV delivery reformulate to SC
- The co-formulation of antibodies with hyaluronidase allows the injection to be completed in 3-5 minutes instead of hours of intravenous infusion.

Amino acid sequence of Hysorptase<sup>®</sup> is the same with Halozyme's, whose core patent in the US will expire in 2027.9.23 and has expired in other areas.

# Challenges of Current Drug Delivery and BaoPharma's Solution

A decade of expertise in hyaluronidase to effectively meet diverse client challenges

## Challenges of Intravenous (IV) Administration

- Limited availability of infusion chairs in clinics and hospitals.
- Shortage of nurses to manage IV treatments.
- Pharmacy supply chains struggle to keep pace with growing demand.
- Long waiting times for patients to receive treatment.
- Critically ill patients often face delays in starting therapy.




## Subcutaneous Delivery Enhanced by Hysorptase®

- Reduces the treatment time from hours to just minutes.
- Lowers the incidence of infusion-related side effects.
- Enables treatment to be administered in more convenient settings, such as at home or in smaller medical facilities.
- Patients overwhelmingly prefer subcutaneous delivery: 81-89% of patients choose SC over IV when given the option.



## Addressing the Diversity of Drug Development Needs:

- For drugs that can be co-formulated or require separate dosing, BaoPharma provides three ready-to-use product options:




# Hysorptase® in High-Concentration for Co-Formulation

For the co-formulation of biologics such as antibodies, ADCs, enzymes, as well as certain small molecules

## Co-formulation with rHuPH20

The leading approach for large volume sc antibody therapies currently on the market.



## ► Hysorptase® in High Concentration

### ● Cost-effective enzyme, simplified formulation:

With BaoPharma's low-cost PH20 enzyme, clients no longer need to prioritize increasing antibody concentrations to reduce enzyme usage. This makes s.c. formulation more accessible, even for abs that can't achieve high concentrations, effectively removing a key barrier.

### ● Ready-to-use Format in Stock:

BaoPharma offers high-concentration hyaluronidase solution, ready for direct dilution in the development, production, and commercialization of co-formulated antibody therapies.

### ● Global Supply & Expert Support:

BaoPharma provides readily available stock with full support from a professional team, ensuring smooth development and commercialization.

# Hysorptase® in Low-Concentration for Combination

For subcutaneous delivery of drugs that cannot be developed as co-formulations

## Combination with rHuPH20

The marketed combination product HyQvia enables 25mL s.c. injection of 10% immunoglobulin with 200 units of rHuPH20.



HyQvia

[Immune Globulin Infusion 10% (Human)  
with Recombinant Human Hyaluronidase]



## ► Hysorptase® in Low Concentration

- **Compatible with any molecule type:**

Developing subcutaneous formulations through co-packaging eliminates formulation barriers. The production process for combination products requires no adjustments.

- **Ready-to-use Format in Stock:**

BaoPharma provides liquid form of low concentration Hysorptase® for combination product development, production and commercialization.

- **Global Supply & Expert Support:**

BaoPharma provides readily available stock with full support from a professional team, ensuring smooth development and commercialization.

# Collaboration

## Driving Innovation in Subcutaneous Delivery



**30+** Products in Development

**1** Product in Phase 1

**1** Product in Phase 2

**1** Product in Phase 3

| Product                                   | Indication   | Pre-Clinical | Phase I | Phase II                | Phase III | Partners                     |
|---|--|--------------|---------|-------------------------|-----------|------------------------------|
| anti-CD20 mAb SC                          | Generalized Myasthenia Gravis  |              |         |                         |           |                              |
| SG301 SC an anti-CD38 mAb                 | Systemic Lupus Erythematosus   |              |         |                         |           |                              |
| KJ015 an anti-Her2 BiAb                   | HER2 positive cancers  |              |         | NMPA / FDA              |           | Self-owned                   |
| Undisclosed (Combination packaging)       | Infections   |              |         | NMPA / EMA              |           | Undisclosed                  |
| Undisclosed                               | Autoimmune diseases  |              |         |                         |           | Undisclosed                  |
| Undisclosed (Biosimilar)                  | Undisclosed  |              |         | Global: FDA / EMA / ... |           | Undisclosed                  |
| Undisclosed                               | Platform collaboration   |              |         | Global                  |           | A world-leading CDMO company |
| Recombinant Human Hyaluronidase Injection | as "An adjuvant to increase the dispersion and absorption of other injected drugs" |              |         |                         |           | Self-owned                   |

BaoPharma actively explores subcutaneous applications of our enzymes, proactively identifying viable solutions to eliminate development barriers for our clients.

# Business Models

To make subcutaneous drug delivery accessible and affordable for all

## Non-Exclusive

\$ Material  \$ Tech support 

Our primary approach to collaboration is through a non-exclusive license, with material supply and technical support as the main components of the cost.

- **High-quality, large-scale production:** With significant capacity and strict quality control measures, we provide high-quality hyaluronidase at competitive prices.
- **No barriers for entry:** Our non-exclusive collaboration model ensures easy access for pharmaceutical companies of any size.
- **Competitive Pricing:** BaoPharma offers cost-effective PH20 with a pricing model that ensures our enzyme is among the most affordable on the market, supported by efficient supply and comprehensive technical assistance to meet your development needs.

# About BaoPharma

To make subcutaneous drug delivery accessible and affordable for all

| Product                            | Indication   | IND | Phase I | Phase II | Phase III | BLA |
|------------------------------------|--|-----|---------|----------|-----------|-----|
| KJ017<br>Recombinant hyaluronidase | as "An adjuvant to increase the dispersion and absorption of other injected drugs" |     |         |          |           |     |
| Ricefidase<br>IgG-degrading enzyme | multiple indications   |     |         |          |           |     |
| KJ101<br>Recombinant Chymotrypsin  | multiple indications   |     |         |          |           |     |
| KJ015<br>Anti-HER2 BiAb, S.C.      | Tumors   |     |         |          |           |     |
| SJ02<br>FSH-CTP                    | ART  |     |         |          |           |     |
| SJ04<br>rhCG                       | ART  |     |         |          |           |     |

- Decades of Expertise in Enzyme & Glycoprotein Development**

BaoPharma excels in the development and manufacturing of recombinant proteins.

- Non-Competitive Partner**

We focus on enzyme and glycoprotein development, ensuring no overlap with our clients' products.

- Advanced Manufacturing Capabilities**

Our GMP-compliant facility supports large-scale production, including sterile injectables, lyophilized products, and pre-filled syringes.

- Tailored Client Support**

With 300+ experts, we provide comprehensive support from development to commercial production.





**BAO PHARMA**

---

**Acting on the Needs of Patients**

**For more information, please contact us:**

**SHANGHAI BAO PHARMACEUTICALS CO.,LTD.**

**Address:** 28 Luoxin Road, Baoshan District, Shanghai

**Contact:** Yunxia (Erica) Xu

**E-mail:** [erica.xu@baopharma.com](mailto:erica.xu@baopharma.com)

**Website:** [www.baopharma.com](http://www.baopharma.com)